fred perry
Uschione
- Registrato
- 12/7/05
- Messaggi
- 8.143
- Punti reazioni
- 691
In parallel with preparing to restart PALISADE-2, the Company is planning to meet with the U.S. Food and Drug Administration (FDA) during the First Quarter of calendar 2023 to discuss and reach consensus with the FDA on the next step in the Company’s Phase 3 development program for PH94B as a potential treatment for adults with SAD.